Menu Search
Equities

Agenus Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AJ8:MUN

Agenus Inc

Actions
  • Price (EUR)2.54
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change-18.59%
  • Beta1.6020
Data delayed at least 15 minutes, as of Feb 12 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

  • Revenue in USD (TTM)106.83m
  • Net income in USD-35.38m
  • Incorporated1999
  • Employees316.00
  • Location
    Agenus Inc3 Forbes RdLEXINGTON 02421-7305United StatesUSA
  • Phone+1 (781) 674-4410
  • Fax+1 (781) 674-4200
  • Websitehttps://agenusbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.